妊娠期肥胖的药物治疗:现有与新兴疗法的综述
本综述系统检索文献,评估妊娠期肥胖的药物治疗证据。二甲双胍、奥利司他等现有药物因疗效有限或安全性数据不一致而应用受限;GLP-1受体激动剂虽在肥胖治疗中变革性发展,但因安全性信息不足不推荐妊娠期使用。未来需通过妊娠登记等协作研究确定高风险病例中的潜在角色。
要点
- 现有减肥药物在妊娠期应用受限,主要因疗效有限或安全性数据不一致。
- GLP-1受体激动剂不推荐妊娠期使用,安全性信息不足。
- 临床指南仍支持遵循美国国家医学院的妊娠期体重增长目标。
核心结论
- 妊娠期肥胖药物治疗证据有限,现有药物应用受限,新兴药物安全性未确立。
- GLP-1受体激动剂目前不推荐妊娠期使用,需更多研究评估高风险病例中的潜在角色。
研究设计与样本
- 本综述系统检索文献,评估妊娠期历史性和新兴减肥疗法的证据。
主要发现
- 二甲双胍、奥利司他和纳曲酮-安非他酮因疗效有限或安全性数据不一致而应用受限。
- GLP-1受体激动剂在肥胖治疗中具变革性,但妊娠期安全性信息不足。
- 动物研究提示GLP-1受体激动剂可能影响胎儿生长,但大型人类观察性研究在调整混杂因素后未显示重大先天畸形独立风险显著增加。
临床怎么用
- 临床应继续遵循美国国家医学院的妊娠期体重增长目标,尤其肥胖女性推荐适度增重。
- 妊娠期不推荐使用GLP-1受体激动剂,现有减肥药物需谨慎评估风险获益。
局限性
- 现有药物疗效有限或安全性数据不一致,新兴药物缺乏妊娠期安全性信息。
- 需妊娠登记等稳健协作研究以确定新兴药物在高风险病例中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The escalating prevalence of maternal obesity and excess gestational weight gain poses significant risks to both maternal and child health. Current management strategies, primarily focused on lifestyle interventions, often have limited efficacy, creating an urgent unmet clinical need. This review summarises the evidence for pharmacological management of obesity in pregnancy. We systematically searched the literature to evaluate historical and emerging weight management therapies for use in pregnancy. Existing medications such as metformin, orlistat, and naltrexone-bupropion have limited application due to modest efficacy or inconsistent safety data. Newer agents like glucagon-like peptide-1 (GLP-1) receptor agonists are transforming obesity care but are not currently recommended during pregnancy due to insufficient safety information. While animal studies have raised concerns regarding foetal growth, large human observational studies have not yet demonstrated a significant independent risk of major congenital malformations after accounting for confounding maternal comorbidities. Future progress depends on robust, collaborative research, including pregnancy registries, to determine if these agents could have a role in carefully selected, high-risk cases. Clinical guidance continues to support adherence to National Academy of Medicine gestational weight-gain targets, particularly the modest recommended gain for women with obesity.
引用
- Fotheringham P, McGee RG, Chang R, et al. Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies. Drugs. 2026. PMID: 41619150. doi:10.1007/s40265-025-02279-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。